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ABSTRACT
Epilepsy and migraine are common neurological diseases in many populations. Mutation 
of the voltage gated natrium channel Nav1.1 (SCN1A) are important causes of different 
genetic epilepsies and can also cause familial hemiplegic migraine (FHM-III). This study 
aimed to identify SCN1A gene variation in patients with epilepsy and common migraine. 
Gene variation analysis of exon 26 of the SCN1A gene was carried out in 33 patients with 
epilepsy, 33 patients with migraine and 30 control individuals from Neurology Polyclinic at 
Dr. Zainoel Abidin General Hospital, Banda Aceh. The PCR and direct sequencing methods 
were performed in this study. SCN1A gene variations were identified in two epilepsy 
patients. These gene variations located at exon 26 were four silent mutations in patient 
E27 at position A4440T (Leu1480Leu), T4443C (Leu1481Leu), A5046G (Leu1682Leu) 
and C5121T (Asp1707Asp). One silent mutation in patient E30 at position G5505A 
(Glu1835Glu). None of these gene variations were identified in controls and patients with 
common migraine in this study. This study has identified 5 genetic variations of SCN1A 
in patients with epilepsy but not in common migraine. The mechanism and relationship 
between these variants and epilepsy need to be clarified.
ABSTRAK
Epilepsi dan migrain adalah penyakit neurologis yang umum di banyak populasi. Mutasi 
voltage gated natrium channel (SCN1A) adalah penyebab penting dari berbagai epilepsi 
genetik dan juga dapat menyebabkan migrain hemiplegik familial (FHM-III). Penelitian ini 
bertujuan untuk mengidentifikasi variasi gen SCN1A pada pasien dengan epilepsi dan 
migrain umum. Analisis variasi gen ekson 26 dari gen SCN1A dilakukan pada 33 pasien 
epilepsi, 33 pasien migrain dan 30 orang kontrol dari Poliklinik Neurologi di Rumah Sakit 
Umum Dr. Zainoel Abidin, Banda Aceh. PCR dan metode direct sequencing dilakukan 
dalam penelitian ini. Variasi gen SCN1A diidentifikasi pada dua pasien epilepsi. Variasi 
gen tersebut terletak pada ekson 26 dimana empat mutasi diam pada pasien E27 pada 
posisi A4440T (Leu1480Leu), T4443C (Leu1481Leu), A5046G (Leu1682Leu) dan C5121T 
(Asp1707Asp). Satu mutasi diam pada pasien E30 pada posisi G5505A (Glu1835Glu). 
Tidak satu pun dari variasi gen tersebut teridentifikasi pada kontrol dan pasien dengan 
migrain umum dalam penelitian ini. Studi ini telah mengidentifikasi 5 variasi genetik 
SCN1A pada pasien dengan epilepsi tetapi tidak pada migrain umum. Mekanisme dan 
hubungan antara varian dan epilepsi ini perlu diklarifikasi.
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INTRODUCTION
The SCN1A gene encodes the alpha 
subunit of a sodium channel called NaV1.1. 
which controls the flow of sodium ions 
into cells (neuron). In the central nervous 
system, NaV1.1 channels is involved in 
transmitting signals from one nerve cell to 
another. The influx of sodium ions through 
NaV1.1 channels lead to depolarization of 
neuron and release of neurotransmitters into 
synaptic cleft.1 Thus, voltage gated sodium 
channel is essential for the generation of 
cellular excitability. 
Recently, this channel was studied 
as a target of antiepileptic drugs since its 
mutations are important causes of genetic 
epilepsy syndrome.2 The SCN1A (NaV1.1) 
is one of the gene which is most clinically 
relevant epilepsy (MIM#182389) with 
hundreds of mutations reported thus far 
in different genetic epilepsy syndromes 
characterized by variable phenotypes.3 
Mutation of this channel is also reported to 
cause some familial hemiplegic migraine 
(FHM-type III; MIM#609634). Familial 
hemiplegic migraine (FHM) is a rare severe 
autosomal dominant inherited subtype 
of migraine with aura characterized by 
hemiparesis during the attacks. Some FHM 
families carry missense NaV1.1 mutations, 
in some cases without any signs of epileptic 
phenotypes.4
The missense mutations change an 
amino acid in the Nav1.1 channel, which 
alters the channel’s structure and function. 
The abnormal channels stay open longer than 
usual, which increases the flow of sodium 
ions into neurons. This increase triggers 
the cell to release more neurotransmitters.5 
However, interpretation of genetic variant 
is challenging, especially in multifactorial 
diseases like epilepsies and common 
migraine. This study aimed to identify 




Genetic analysis was performed in 33 
epilepsy patients (16 women and 17 men). 
Of all patients, 4 were generalized epilepsy 
and 29 were partial secondary generalized 
epilepsy. Thirty three migraine patients (27 
women and 6 men) were involved included 
16 patients without aura (MO) and with aura 
(MA). In addition, 30 individuals (without 
epilepsy or migraine) from Policlinic of 
Neurology, Dr. Zainoel Abidin General 
Hospital, Banda Aceh were recruited as 
control. Written informed consent was 
obtained from each subject involved in the 
study. Protocol of the study was approved 
by the Research Ethics Committee, Faculty 
of Medicine, Universitas Sumatera Utara, 
Medan, Indonesia in compliance with the 
national legislation and the code of ethical 
principles for Medical Research involving 
human subjects of the World Medical 
Association. Venous bloods were drawn 
from all subjects after an informed consent 
obtained.
Molecular analysis
Genomic DNA extracted from 
peripheral blood leukocytes using standard 
salting-out method. Hot spot mutation of this 
gene, exon 26, was divided into 3 fragments 
and amplified by polymerase chain reaction 
(PCR) followed by a direct sequencing using 
an ABI BigDye terminatorcycle sequencing 
kit (Applied Biosystems). The primer used 
in this study were fragment A forward (F) 5’- 
AGG ACT CTG AAC CTT ACC TTG -3’ , 
reverse (R) 5’- TAC ATG TTC ACC ACA 
ACC AGG -3’ ; fragment B (F) 5’- TAA 
CCC TGG AAG CTC AGT TAA G -3’ , (R) 
5’- TGA TTG GCT GAT AGG AGA CCT T 
-3’ ; fragment C (F) 5’- TTG CTT TTA CAA 
AGC GGG TTC T -3’ ; (R) 5’- GTT TGC 
TGA CAA GGG GTC AC -3’.
426
Lestari ND, et al., SCN1A exon 26 variants in epilepsy...
RESULTS
SCN1A heterozygous gene variations 
were identified in two epilepsy patients. 
These gene variations located exon 26 
were four silent mutations in patient 
E27 (a man, 32 years old with epilepsy 
partial secondary generalized) at position 
4440 causing silent mutation codon 1480 
CTA→CTT (Leu1480Leu), at potition 4443 
silent mutation codon 1481 CTT→CTC 
(Leu1481Leu), nucleotide change also 
at position 5046 causing silent mutation 
codon 1682 CTA→CTG (Leu1682Leu) and 
nucleotide change at position 5121 causing 
silent mutation codon 1707 AAC→AAT 
(Asp1707Asp). One silent mutation in 
patient E30 (a woman, 19 years old with 
epilepsy partial secondary generalized) at 
position 5505 causing silent mutation codon 
1835 GAG→GAA (Glu1835Glu). None 
of these gene variations were identified in 
controls and common migraine patients in 
this study.
DISCUSSION
Unlike some disorders where mutations 
are largely concentrated in ‘hot spots’, the 
mutations within SCN1A are widely 
distributed throughout the gene.6,7 Only exon 
26 was sequenced in this study because of 
exon 26 is longer than other SCN1A exons 
and data from previous studies in Indonesian 
patients reported that mutation in exon 26 
were more frequent.8 Some experiment have 
done to prove mutation of gene SCN1A in 
epilepsy or migraine patients. Mulley et al.6 
stated that of all the known epilepsy genes, 
SCN1A was the most clinically relevant, 
with the largest number of epilepsy-related 
mutations characterized to that time. Escayg 
et al.9 identified 2 missense mutations. The 
mutant residues thr875 (see182389.0002) 
and arg1648 (see182389.0001) are located 
in the S4 transmembrane segments of the 
sodium channel alpha-subunit, which is 
comprised of 4 homologous domains (D1-
D4), each containing 6 transmembrane 
segments. Orrico et al.10 identified 21 
mutations, including 14 novel mutations, in 
the SCN1A gene in 22 (14.66%) of 150 
Italian pediatric patients with epilepsy. 
SCN1A mutations were found in 21.2% of 
patients with (generalized epilepsy with 
febrile seizure plus) GEFS+ and in 75% of 
patients with Dravet syndrome from the 
overall patient cohort. Mutation in the 
SCN1A gene can cause a spectrum of early-
onset epileptic encephalopathies 
(EIEE6;607208), with the most common 
designation being Dravet syndrome.9 In 14 
patients, including a pair of monozygotic 
twins, with classic symptoms of severe 
myoclonic epilepsy in infancy (SMEI), 
Sugawara et al.11 identified 10 heterozygous 
mutations in the SCN1A gene. There were 3 
frame-shift mutations which resulted in 
intragenic stop codons and truncated 
channels, and 7 nonsense mutations which 
also resulted in truncated channels. In 29 
patients with SMEI and 11 patients with 
other types of epilepsy, Ohmori et al.12 
performed a mutation search of the SCN1A 
gene. They detected mutations in 24 of the 
29 patients with SME, but none of the 
patients with other types of epilepsy. The 
mutations included deletions, insertions, 
missense changes, and nonsense changes. 
They could not find SCN1A mutations in 
any of the parents, suggesting that de novo 
mutation in the SCN1A gene occurred in the 
course of meiosis in the parents.12 Claes et al.13 
investigated 9 patients with Dravet syndrome 
and observed 8 coding and 1 non-coding 
mutation in the SCN1A gene. In contrast to a 
previous study of 7 isolated patients, most 
mutations were found to be missense 
mutations clustering in the S4-S6 region of 
SCN1A. These findings demonstrated that 
de novo mutations in SCN1A are a major 
cause of isolated Dravet syndrome.13 In 7 of 
10 unrelated patients with intractable 
childhood epilepsy with generalized tonic-
clonic seizures, a variant of Dravet syndrome 
without myoclonus, Fujiwara et al.5 identified 
heterozygous mutations in the SCN1A gene. 
All of the mutations were missense 
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mutations. The findings extended the 
phenotypic spectrum associated with 
mutations in the SCN1A gene.5 Zucca et al.14 
identified 13 mutations, including 12 novel 
mutations, in the SCN1A gene in 12 (20%) 
of 60 unrelated patients with cryptogenic 
epilepsy beginning in the first 2 years of life. 
Depienne et al.15  identified pathogenic 
mutations or deletions, including 161 novel 
point mutations, in the SCN1A gene in 242 
(73%) of 333 patients with Dravet syndrome. 
The most common mutations were missense 
(42%), and 14 patients had micro 
arrangements in or deletions of the gene. 
Thus, the disease mechanism appeared to be 
haploin sufficiency of the SCN1A gene. 
Mutations were scattered throughout the 
gene, and there were no apparent genotype/
phenotype correlations.15 Orrico et al.10 
identified 21 mutations, including 14 novel 
mutations, in the SCN1A gene in 22 (14.66%) 
of 150 Italian pediatric patients with epilepsy. 
SCN1A mutations were found in 21.2% of 
patients with GEFS+ and in 75% of patients 
with Dravet syndrome from the overall 
patient cohort. Tate et al.16 identified a G-to-A 
polymorphism in the SCN1A gene 
(rs3812718;182389.0016) that affects 
alternative splicing of exon 5. The major A 
allele disrupts the consensus sequence of the 
fetal/neonatal exon 5N, reducing the 
expression of this exon relative to the adult 
exon 5A. Two antiepileptic drugs, 
carbamazepine and phenytoin, act by binding 
to the alpha-subunit of neuronal sodium 
channels encoded by SCN1A.16 The findings 
emphasized an emerging role of genetic 
polymorphisms in modulation of drug effect, 
and illustrated the importance of considering 
the activity of compounds at alternative 
splice forms of drug targets.17 Mulley et al.6 
found that the more than 100 epilepsy-
associated mutations reported in the SCN1A 
gene to that time were spread throughout the 
gene. Some clustering of mutations was 
observed in the C terminus and the loops 
between segments 5 and 6 of the first 3 
domains of the protein. Kanai et al.18 performed 
a meta analysis of the physiochemical effects 
of amino acid substitutions resulting from 
missense mutations in the SCN1A gene and 
their phenotypes in order to assess genotype/
phenotype correlations. From 33 articles, 
they studied 155 missense mutations, 
including 22 associated with GEFS+, 14 
associated with an intermediate phenotype 
(e.g., T1709I;182389.0013), and 119 
associated with a severe phenotype.18 Herini 
et al.8 identified two novel SCN1A mutations 
in Indonesian children diagnosed as having 
SMEI and SMEB (Severe myoclonic 
epilepsy in infancy borderline), there were at 
nucleotide 4834 (c.4834G>A) in exon 25 
leading to substitution of valine with 
isoleucine at at amino acid position 1612 
(p.V1612I) and at nucleotide 5266 
(c.5266T>G) in exon 26 leading to 
substitution of cysteine with glycine at 
amino acid 1756 (p.C1756G).8 In our study, 
SCN1A gene variations were identified in 
two epilepsy patients. These gene variations 
located at exon 26 were four silent mutations 
in patient E27 at position A4440T 
(Leu1480Leu), T4443C (Leu1481Leu), 
A5046G (Leu1682Leu) and C5121T 
(Asp1707Asp). One silent mutation in 
patient E30 at position G5505A 
(Glu1835Glu). None of these gene variations 
were identified in controls and common 
migraine patients in this study. This study 
has identified 5 genetic variations of SCN1A 
in patients with epilepsy but not in common 
migraine. The mechanism and relationship 
between these variants and epilepsy need to 
be clarified. But, may be it happen because 
of reducing sodium currents in GABAergic 
inhibitory interneurons resulting from 
heterozygous SCN1A mutations that may 
cause the hyperexcitability that leads to 
epilepsy.19 The majority of SCN1A mutations 
cluster in the C-terminus and the pore loops 
in the first three domains of the protein.6 The 
pathophysiology of SCN1A mutations is a 
decrease in the activity of GABAergic 
inhibitory neurons. For example, most of the 
mutations that cause Dravet syndrome 
(SMEI) result in loss of function, whereas 
mutations that cause GEFS+ are missense, 
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likely altering channel activity.9 Ogiwara et 
al.20 concluded that haplo insufficiency of the 
SCN1A gene underlies seizures. This study 
has identified no genetic variations of 
SCN1A in patients with common migraine. 
Mutation of SCN1A commonly found in 
patients with familial hemiplegic migraine. 
In affected members of 3 European families 
with familial hemiplegic migraine-3 (609634), 
Dichgans et al.21 identified a heterozygous 
4465C-A transversion in exon 23 of the 
SCN1A gene, resulting in a gln1489-to-lys 
(Q1489K) substitution in the cytoplasmic 
linker between domains III and IV, which is 
critical for fast inactivation. Dichgans et al.21 
suggested that the mutation may facilitate 
initiation and propagation of cortical 
spreading depression, which is thought to be 
related to migraine aura. FHM-III mutation 
accelerates recovery from fast inactivation 
of Na(V)1.5 (presumably Na(V)1.1) 
channels. SCN1A mutation has effects on the 
gating properties of neuronal voltage-gated 
Na(V)1.1 Na+channel consistent with both 
hyperexcitability and hypoexcitability. This 
self-limited capacity may be a specific 
characteristic of migraine mutations.22 Some 
FHM-III mutations resulted in gain of 
function (familial hemiplegic migraine and 
generalized epilepsy) such as L263V and 
L1649Q, but some mutations resulted in loss 
of function (typical familial hemiplegic 
migraine) such as Q1489K. These results 
emphasize that migraine and epilepsy may 
share common molecular mechanisms.23 The 
T1174SSCN1A mutation can lead to a gain of 
function in some conditions and loss of 
function in other conditions. These findings 
may help to explain the coexistence of 
epilepsy and familial hemiplegic migraine 
without epilepsy in the same family.22 
Bioinformatics analysis of the 3 familial 
hemiplegic migraine mutations shows that 
FHM-III is more resistant to mutation within 
the amino acid sequence when compared 
with others.24 This expanded list of mutations, 
taken together with those reviewed by 
Mulley et al.6 provides an essential mutational 
database for use as an interpretative aid for 
diagnostic laboratories offering SCN1A 
mutation testing.
CONCLUSION
This study has identified 5 genetic 
variations of SCN1A in two patients with 
epilepsy but not in common migraine. The 
mechanism and relationship between these 
variants and epilepsy need to be clarified.
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